Akums Drugs and Pharmaceuticals share news, announcements and annual reports
NSE: AKUMSBSE: 544222Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 30 Oct 2026. Previous close ₹741.05.
30 Oct: open ₹750.00, high ₹755.00, low ₹722.75
- Next results date: the board meets on 2 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹11,517 Cr630th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 39.48
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.48
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.41%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 9.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.02
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,45,38149.5% delivered
Akums Drugs and Pharmaceuticals has 155 announcements on record, routine notices left out; 5 in the 30 days to 1 Nov 2026, the latest on 31 Oct 2026.
Next board meeting and results date
As the company gave notice to the exchange.Akums Drugs and Pharmaceuticals quarterly results
The board meets on 2 Nov 2026 to consider financial results
Notice filed 28 Oct 2026
Akums Drugs and Pharmaceuticals annual reports, presentations and earnings calls
The company's own documents, latest first.Akums Drugs and Pharmaceuticals financials, year by year
Annual reports2
- Annual report, year to Mar 202618 Jun 2026
- Annual report, year to Mar 202524 Jun 2025
Investor presentations9
- Presentation8 Aug 2026
- Investor Presentation14 May 2026
- Investor Presentation13 Feb 2026
- Investor Presentation13 Nov 2025
- Presentation8 Aug 2025
4 earlier presentations
- Investor Presentation26 May 2025
- Investor Presentation6 Feb 2025
- Investor Presentation9 Nov 2024
- Investor Presentation24 Aug 2024
Earnings calls19
- Transcript13 Aug 2026
- Link of Recording10 Aug 2026
- Transcript of Investors/Analysts Conference Call held for un-audited financial results of Q4 FY 2025-26 and audited financial results for FY 2025-2621 May 2026
- Link of Audio Recording of Investor/Analysts Conference Call18 May 2026
- Transcript19 Feb 2026
14 earlier call documents
- Transcript19 Feb 2026
- Link of Recording16 Feb 2026
- Transcript17 Nov 2025
- Link of Recording14 Nov 2025
- Transcript18 Aug 2025
- Link of Recording11 Aug 2025
- Transcript2 Jun 2025
- Link of Recording27 May 2025
- Transcript11 Feb 2025
- Link of recordings7 Feb 2025
- Transcript15 Nov 2024
- Link of Recording11 Nov 2024
- Transcript4 Sep 2024
- Link of Recording30 Aug 2024
Akums Drugs and Pharmaceuticals share news and announcements
Newest first. Page 1 of 4.
Oct 2026
31 Oct · Management
31 Oct · Management
28 Oct · Analysts
15 Oct · Legal
Sep 2026
23 Sep · Analysts
16 Sep · Analysts
3 Sep · General Updates
Aug 2026
25 Aug · Analysts
13 Aug · Analysts
10 Aug · Analysts
10 Aug · Business
8 Aug · Business
8 Aug · Results
5 Aug · Analysts
5 Aug · Board meeting
Jul 2026
10 Jul · Meeting
Jun 2026
18 Jun · Meeting
16 Jun · General Updates
10 Jun · Analysts
9 Jun · Analysts
3 Jun · Analysts
May 2026
28 May · Analysts
18 May · Disruption of Operations
16 May · Disruption of Operations
14 May · Business
14 May · Business
14 May · General Updates
14 May · Results
12 May · Analysts
8 May · General Updates
Apr 2026
29 Apr
11 Apr · Rating
Feb 2026
26 Feb · Analysts
16 Feb · Analysts
13 Feb · Analysts
13 Feb · Business
13 Feb · Business
How the price met the news
The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts). Delivery against usual in the glossary
- 13 Apr 2026Credit ratingup 1.64%+2.4 pts vs Nifty 500market median 0.0% · five sessions +3.4% (+1.0 pts vs Nifty 500) · volume 2.1× usual · delivery −4.7 pts against usual · The announcement
- 14 Nov 2025Resultsdown 3.00%−3.1 pts vs Nifty 500market median −0.7% · five sessions −3.6% (−4.3 pts vs Nifty 500) · volume 6.1× usual · delivery +2.3 pts against usual · The announcement
- 11 Aug 2025Resultsdown 0.15%−1.0 pts vs Nifty 500market median −0.7% · five sessions −1.2% (−3.4 pts vs Nifty 500) · volume 3.3× usual · delivery −36.6 pts against usual · The announcement
- 27 May 2025Resultsdown 0.78%−0.4 pts vs Nifty 500market median −0.7% · five sessions −2.3% (−2.0 pts vs Nifty 500) · volume 7.4× usual · delivery −19.2 pts against usual · The announcement
- 7 Feb 2025Resultsdown 2.35%−2.2 pts vs Nifty 500market median −0.7% · five sessions −4.2% (−0.6 pts vs Nifty 500) · volume 0.9× usual · delivery −5.0 pts against usual · The announcement
- 11 Nov 2024Resultsdown 10.00%−9.8 pts vs Nifty 500market median −0.7% · five sessions −30.5% (−27.2 pts vs Nifty 500) · volume 2.8× usual · delivery +11.4 pts against usual · The announcement
- 10 Oct 2024Credit ratingup 0.28%+0.3 pts vs Nifty 500market median 0.0% · five sessions +8.1% (+7.8 pts vs Nifty 500) · volume 0.8× usual · delivery −21.5 pts against usual · The announcement
- 26 Aug 2024Resultsdown 5.00%−5.6 pts vs Nifty 500market median −0.7% · five sessions −8.1% (−9.5 pts vs Nifty 500) · delivery +5.0 pts against usual · The announcement
Akums Drugs and Pharmaceuticals results filing dates and deadlines
Listed companies must file quarterly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.